In human hepatocellular carcinoma, deguelin exerts potent anti angiogenic effects by specifically acting on the hepatocyte growth factor receptor (HGF-c-Met) and VEGF-VEGFR pathways in cancer cells and endothelial cells, respectively (Li, Yu, Li, et al., 2018). Here, HGF is linked to cancer.